Durvalumab (Imfinzi, AstraZeneca AB), also known as MEDI4736, is a human IgG1 mAb directed to the PD-L1 molecule approved by the FDA for the treatment of locally advanced or metastatic urothelial cancer, as well as stage III NSCLC, in inoperable and non-responder patients. Here, CD274 is linked to non-small cell lung carcinoma.